Colinz Laboratories Limited, a prominent player in the pharmaceutical sector, has announced significant corporate decisions following its recent Board of Directors meeting. The company has approved its unaudited financial results for the quarter ended June 30, 2025, and made key appointments to strengthen its leadership team.

Financial Results and Corporate Governance

The Board of Directors convened on July 31, 2025, to review and approve the unaudited financial results for the first quarter of the fiscal year 2025-26. In compliance with SEBI regulations, the company's statutory auditors conducted a limited review of these results. Additionally, the Board approved the Director's Report, Management Discussion Report, Corporate Governance Report, and CEO's certification for the year ended March 31, 2025.

Key Appointments and Reappointments

In a move to bolster its leadership, Colinz Laboratories has made two significant appointments:

1. Mr. Swapnil Jayeshbhai Madiyar (DIN: 08520796) has been recommended for appointment as a Non-Promoter, Non-Executive Director, effective September 30, 2025. Mr. Madiyar brings a wealth of experience across key business verticals, including Technology, HR, Marketing, Operations, and General Management.

2. Mr. N. K. Menon (DIN: 01111297) has been recommended for reappointment as Whole Time Director and CEO for a one-year term from October 1, 2025, to September 30, 2026.

Both appointments are subject to shareholder approval at the upcoming Annual General Meeting (AGM).

Annual General Meeting and Auditor Appointments

The company has scheduled its 39th AGM for September 30, 2025, to be held via video conference. The register of members will remain closed from September 23 to September 30, 2025, for the purpose of the AGM.

In other governance matters, Colinz Laboratories has appointed:

• M/s. Sanjay Dholakia & Associates as the Secretarial Auditor for the financial year 2025-26.
• CA Ajay Ramsevak Sharma (Firm Reg. no. 137003W) as the Internal Auditor for the financial year 2025-26.

E-voting Details

For the upcoming AGM, the company has set September 23, 2025, as the cut-off date for determining eligible shareholders for e-voting. The e-voting period will be open from September 27, 2025 (9:30 A.M. IST) to September 29, 2025 (5:00 P.M. IST).

These developments underscore Colinz Laboratories' commitment to corporate governance and strategic growth as it moves forward in the dynamic pharmaceutical industry.

Colinz Laboratories Limited , a prominent player in the pharmaceutical sector, has announced several key decisions following its recent Board of Directors meeting. The company has approved its unaudited financial results for the quarter ended June 30, 2025, and made significant changes to its leadership team.

Financial Results and Governance

The Board of Directors convened on July 31, 2025, to review and approve the unaudited financial results for the first quarter of the fiscal year 2025-26. These results, prepared in accordance with Regulation 33(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, have undergone a limited review by the company's statutory auditors.

In addition to the quarterly results, the Board also gave its approval to the Director's Report for the year ended March 31, 2025. Other key documents approved include the Management Discussion Report, Corporate Governance Report, and CEO's certification for the same period.

Leadership Changes and Appointments

The Board has recommended two significant appointments, subject to shareholder approval at the upcoming Annual General Meeting (AGM):

1. Mr. Swapnil Jayeshbhai Madiyar (DIN: 08520796) has been proposed as a Non-Promoter, Non-Executive Director, effective September 30, 2025. Mr. Madiyar brings a wealth of experience across key business verticals, including technology, HR, marketing, and operations, with a particular focus on the fintech domain.

2. Mr. N. K. Menon (DIN: 01111297) has been recommended for reappointment as Whole Time Director and CEO for a one-year term, from October 1, 2025, to September 30, 2026.

Annual General Meeting and Auditor Appointments

Colinz Laboratories has scheduled its 39th Annual General Meeting for September 30, 2025, to be held via video conference at 2:30 PM. The register of members will remain closed from September 23 to September 30, 2025 (both days inclusive) for the purpose of the AGM.

The company has also made key appointments in its audit functions:

• M/s. Sanjay Dholakia & Associates, Practising Company Secretaries, have been appointed as the Secretarial Auditor for the financial year 2025-26.
• CA Ajay Ramsevak Sharma (Firm Reg. no. 137003W) has been appointed as the Internal Auditor for the same period.

Investor Participation

For the upcoming AGM, the company has set September 23, 2025, as the cut-off date for determining shareholder eligibility for electronic voting. Eligible shareholders can cast their votes electronically from September 27, 2025 (9:30 AM IST) to September 29, 2025 (5:00 PM IST).

These developments underscore Colinz Laboratories' commitment to transparent governance and strategic growth as it moves forward in the dynamic pharmaceutical industry.